Zanamivir in the treatment of influenza

Bibliography

• CALFEE DP, HAYDEN FG: New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs (1998) 56:537–553.
   Google Scholar
• GUBAREVA LV, KAISER L, HAYDEN FG: Influenza virus neuraminidase inhibitors. Lancet (2000) 355(9206):827–835.
   PubMed Web of Science ®Google Scholar
• MCKIMM-BRESCHKIN JL: Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother (2002) 3(2):103–112
   PubMedGoogle Scholar
• FREUND B, GRAVENSTEIN S, ELLIOTT M, MILLER I: Zanamivir. A review of clinical safety. Dug Safety (1999) 21(4):267–281.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of safety issues.
   Google Scholar
• ZAMBON MC: Epidemiology and pathogenesis of influenza. I Antimicrobial Chemother (1999) 44(Suppl. B):3–9.
   Google Scholar
• VARGHESE JN, LAVER WG, COLMAN PM: Structure of the influenza virus glycoprotein antigen neuraminidase at 2,9. A resolution. Nature (1983) 303:35–40.
   PubMed Web of Science ®Google Scholar
• COLMAN PM, VARGHESE JN, LAVER WG: Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature (1983) 303:41–44.
   PubMed Web of Science ®Google Scholar
• VON ITZSTEIN M, WU W-Y, KOK GBet al: Rational design of potent sialidase- based inhibitors of influenza virus replication. Nature (1983) 363:418–423.
   Google Scholar
• MEINDL P, TUPPY H: [2-Deoxy-2, 3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2, 3-dehydro-N-acylneuraminic acids]. Hoppe SeylerS a.itschrift fur Physiologische Dwane (1969) 350:1088–1092.
   Google Scholar
• PALESE P, COMPANS RW: Inhibition of influenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): mechanism of action. J. Gen. Viral (1976) 33:159–163.
   PubMed Web of Science ®Google Scholar
• CALFEE DP, PENG AW, CASS LM, LOBO M, HAYDEN FG: Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection Antimicrob. Agents Chemother. (1999) 43(7):1616–1620.
   PubMed Web of Science ®Google Scholar
• CASS LM, BROWN J, PICKFORD M et al.: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmocokinet. (1999) 36\(Suppl. 1):21–31.
   Google Scholar
• ••This is one of a series of papers (including[12,13,191) in a supplement published by Clinical Pharmacokinetics (edited by Aoki FY and Hayden FG), which together, provide a thorough review of pharmacokinetics of zanamivir.
   Google Scholar
• CASS LM, EFTHYMIOPOULOS C, BYE A: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Chi]. Pharmacokinet. (1999) 36\(Suppl. 1):1–11.
   Google Scholar
• BOIVIN G, GOYETTE N, HARDY I, AOKI FY, WAGNER A, TROTTIER S: Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J. Infect. Dis. (2000) 181(4):1471–1474.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, OSTERHAUS AD, TREANOR JJ et al.: Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl. J. Med. (1997) 337:874–880.
   PubMed Web of Science ®Google Scholar
• ••This clinical trial is particularly importantin relation to the use of zanamivir intranasally.
   Google Scholar
• MONTO AS, WEBSTER A, KEENE 0: Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. Antimicrob. Chemother (1999) 44(Suppl. B):23–29.
   Google Scholar
• •An excellent summary of the main clinical trials in adults.
   Google Scholar
• MURPHY KR, EIVINDSON A, PAUKSEN K et al.: Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest. (2000) 5:337–349.
   Web of Science ®Google Scholar
• ••An important contribution in relation tothe use of zanamivir in persons with impaired pulmonary function.
   Google Scholar
• LOUGHLIN JE, ALFREDSON TD, AJENE AN et al: Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Chi]. Ther. (2002) 24:1786–1799.
   Google Scholar
• ••Important in the conteaxt of possiblebronchospasm as a potential side effect of zanamivir.
   Google Scholar
• WEBSTER A, BOYCE M, EDMUNDSON S, MILLER I: Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of health volunteers. Chi]. Pharmacokinet. (1999) 36\(Suppl. 1):51–58.
   Google Scholar
• HAY AJ: The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Sem. Viral. (1992) 3:21–30.
   Google Scholar
• GRAVENSTEIN S, DRINKA P, OSTERWEIL et al.: A multi-center prospective trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control. Conference program and abstracts of the options for control of influenza IV. European Scientific Working Group on Influenza 2000. Abstract W22–1.
   Google Scholar
• MCKIMM-BRESCHKIN JL: Resistance of influenza viruses to neuraminidase inhibitors - a review. Antivir Res. (2000) 47:1–17.
   PubMed Web of Science ®Google Scholar
• ••A valuable review of issues related to viralresistance.
   Google Scholar
• GUBAREVA LV, MATROSOVICH MN, BRENNER MK, BETHELL RC, WEBSTER RG: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. (1998) 178:1257–1262.
   PubMed Web of Science ®Google Scholar
• MCCLELLAN K, PERRY CM: Oseltamivir. A review of its use in influenza. Drugs (2001) 61(2):263–283.
   Google Scholar
• ZAMBON MC, HAYDEN FG: Review: position statement: global; neuraminidase inhibitor susceptibility network. Antiviral Res. (2001) 49:147–156.
   PubMed Web of Science ®Google Scholar
• •An outline of a continuing programme to monitor viral resistance.
   Google Scholar
• WHITELY RJ, HAYDEN FG, REISINGER KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. (2001) 20:127–133.
   PubMed Web of Science ®Google Scholar
• WALKER JB, HUSSEY EK, TREANOR JJ, MONTALVO JRA, HAYDEN FG: Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J. Infect. Dis. (1997) 176:1417–1422.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, TREANOR JJ, BETTS RF eta].: Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 275:295–299.
   Google Scholar
• Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The Management of influenza in the Southern Hemisphere Trialists (MIST) study group. Lancet (1998) 352:1877–1881.
   PubMedGoogle Scholar
• LALEZARI J, CAMPION K, KEENE 0, SILAGY C: Zanamivir for the treatment of influenza A and B infection in high risk patients: a pooled analysis of randomised controlled trials. Arch. Intern. Med. (2001) 161(2):212–217.
   PubMedGoogle Scholar
• HEDRICK JA, BARZILAI A, BEHRE U et al.: Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. (2000) 19:410–417.
   PubMed Web of Science ®Google Scholar
• MAKELA MJ, PAUKSENS K, ROSTILA T et al: Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo controlled European study. J. Infection (2000) 40:42–48.
   PubMed Web of Science ®Google Scholar
• •This clinical trial showed the maximum benefit from zanamivir (2.5 days).
   Google Scholar
• KAISER L, KEENE ON, HAMMOND JM et al: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. (2000) 160:3234–3240.
   PubMedGoogle Scholar
• JOHNY AA, CLARK A, PRICE N, CARRINGTON D, OAKHILL A, MARKS DI: The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant (2002) 29:113–115.
   PubMedGoogle Scholar
• LEVY E: French economic evaluations of influenza and influenza vaccination. Pharmoecorromics (1996) 9\(Suppl. 3):62–66.
   Google Scholar
• SZUCS T: The socio-economic burden of influenza. J. Antimicrob. Chemother. (1999) 44(Suppl. B):11–15.
   Google Scholar
• SZUCS TD: Influenza: the role of burden of illness research. Pharmoecorromics (1999) 16\(Suppl. 1):27–32.
   Google Scholar
• DRINKA PJ GRAVENSTEIN S, KRAUSE P, NEST L, DISSING M, SHULT P: Reintroduction of influenza A to a nursing building. Infect. Control Hosp. Epidemiol (2000) 11:732–735.
   Google Scholar
• MONTO AS, PICHICHERO ME, BLANCKENBERG SJ etal.: Zanamivir
   Google Scholar
• •• prophylaxis: an effective strategy for the prevention of influenza types A and B within households. Infect. Dis. (2002) 186(11):1582–1588.
   Google Scholar
• LODER N: UK government not convinced by claims for flu drug. Nature (1999) 401(6754):631.
   PubMed Web of Science ®Google Scholar
• •Highlights the issue of satisfying the healthcare provider as well as the licensing authority.
   Google Scholar
• HOFFKEN G, GILLISSEN A: Efficacy and safety of zanamivir in patients with influenza — impact of age, severity of infections and specific risk factors. Med. Microbial Immune]. (2002) 191:169–173.
   PubMed Web of Science ®Google Scholar
• ••Stressing the importance of severity ofillness and age as predictors of maximum benefit from treatment with zanamivir.
   Google Scholar
• Guidance to the NHS on zanamivir (Relenza) October 1999. National Institute for Clinical Excellence (1999).
   Google Scholar
• HAYDEN FG, COATS T, KIM K et al.: Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in Phase II clinical trials. Antivit: Ther (2002) 1:53–65.
   Google Scholar
• FLEMING DM: The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun. Dis. Public Health (2000) 1:32–38.
   Google Scholar
• FLEMING DM, ZAMBON M, BARTELDS Al, DE JONG JC: The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Eur. I Epidemial (1999) 5:467–473.
   Google Scholar
• GODDARD NL, JOSEPH CA, ZAMBON M, NUNN M, FLEMING D WATSON JM: Influenza surveillance in England and Wales: October 1999 to May 2000. Commun. Dis. Public Health (2000) 3:262–266.
   Google Scholar
• ROSS AM, KAI J, SALTER R, ROSS J, FLEMING DM: Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors. Commun. Dis. Public Health (2000) 3:256–260.
   PubMedGoogle Scholar
• HAYDEN FG: Perspectives on antiviral use during pandemic influenza 1: Philos. Trans. R. Soc. Land. B. Biol. Li. (2001) 356(1416):1877–1884.
   PubMed Web of Science ®Google Scholar
• •The context of treatment options in a pandemic situation. Affliation
   Google Scholar